Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 20/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15138370 | 1.00 | FGFR2 (1.00) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL17754521 | 0.90 | FGFR2 (1.00) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345724 | 0.90 | FGFR2 (1.00) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345548 | 0.88 | FGFR2 (0.79) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345546 | 0.88 | FGFR2 (0.79) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345658 | 0.87 | FGFR2 (0.81) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL17899397 | 0.87 | FGFR2 (0.81) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL17754522 | 0.87 | FGFR2 (0.81) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15966877 | 0.85 | FGFR2 (0.74) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345726 | 0.83 | FGFR2 (0.71) | FGFR2FGFR1FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | FGFR2 4/4885FGFR1 1/4885FGFR4 3/4885 |
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | FGFR2 3/4885FGFR1 1/4885FGFR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.